Mediatensyl Lp 60 Mg (Urapidil)

Urapidil, the active ingredient in Mediatensyl Lp 60 Mg, is a Alpha-1 adrenergic antagonist presented as a 60 mg tablet for oral use. It treats hypertension in adult patients by lowering peripheral vascular resistance. GNH USA supplies Mediatensyl Lp 60 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Urapidil is employed in the management of high‑blood‑pressure disorders, acting on the peripheral vascular system to achieve controlled reduction of arterial pressure.

Hypertension: provides sustained blood‑pressure lowering in essential hypertension. Hypertensive emergencies: offers rapid vasodilation for urgent blood‑pressure control. Secondary hypertension: assists in lowering pressure when caused by other identifiable conditions.

Urapidil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Flushing or warmth sensation - Nausea or mild gastrointestinal upset - Transient hypotension - Tachycardia

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Allergic reactions such as rash, pruritus, or angioedema - Hepatic enzyme elevation - Cardiac arrhythmias - Acute renal impairment - Severe electrolyte disturbances

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: adjust use in patients with impaired kidney function. - Orthostatic hypotension: advise caution when standing quickly. - Elderly patients: start at lower doses and titrate slowly. - Concomitant antihypertensives: assess for additive effects. - Store at room temperature: keep in the original pack, protect from moisture.

Urapidil can interact with other medicines that influence blood pressure or hepatic metabolism.

Major Interactions (Avoid): - Combined use with other potent vasodilators (e.g., nitroprusside) may cause dangerous hypotension. - Concurrent MAO inhibitors can amplify catecholamine effects.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of volume depletion and hypotension. - Beta‑blockers: require careful blood‑pressure monitoring. - Anesthetic agents: may potentiate circulatory depression during surgery. - CYP3A4 inhibitors: could raise plasma levels of Urapidil. - CYP3A4 inducers: may reduce therapeutic effect.